Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

To address this problem, antibody engineers introduced a serine-to-proline substitution that made the middle hinge region more like that found in IgG1 (ref. 7). This not only gave a more ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

The newly established antibody platform enables the development of high-profile therapeutic strategies with broad applications that will boost cutting-edge discovery programmes across QMUL and Barts ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...

--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company’s technologies were delivered at the 2024 Antibody Engineering & Therapeutics ...

A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.